Founded by Asish Mohandas, Cureous Labs has secured ₹1.66 crore (~$190,000 USD) in seed funding to bring its automated patient repositioning device, Eturnal™, to hospitals and long-term care facilities across India. The round was led by Inflection Point Ventures (IPV) with participation from Anthill Ventures, providing the resources required for scaled manufacturing, product certification and early commercial deployment.

Automating One of Healthcare’s Hardest Manual Tasks

Bedsore-related pressure injuries remain a persistent threat for bedridden patients, costing hospitals time, money and human resources. Traditional care protocols require nurses to manually reposition patients every two hours - a labor-intensive process that drains caregiver capacity and often falls behind during busy shifts.

Eturnal™ changes that dynamic completely. It’s a retrofittable device that integrates directly into existing hospital beds and autonomously handles patient turning, reducing both injury risk and caregiver workload. The system has already amassed more than 30,000 operating hours and performed over 14,000 repositioning cycles across pilots in 100+ hospitals.

What’s powerful here - and what many early-stage founders can take from this - is that Cureous didn’t approach the problem as a “medical device company” trying to build an impressive piece of hardware. They approached it as a systems company, focused on unlocking workforce scale. Instead of building a new device and hoping caregivers adopt it, they built automation that plugs directly into existing workstreams and multiplies output without asking anyone to change their behavior. That’s the founder insight worth underlining: the most valuable products aren’t the ones that look the most innovative - they’re the ones that remove friction from day-to-day operations so quietly that people forget how they worked without them. This is exactly why investors leaned in: the impact is obvious and sustained, not hypothetical.

Where the Seed Funding Goes

Leveraging the new capital, Cureous Labs will focus on:

• Manufacturing its first commercial-scale batch of Eturnal™ units
  
• Establishing a disinfection center to meet safety standards
  
• Completing regulatory certifications and approvals
  
• Hiring in sales, implementation, and post-deployment support
  

Hospitals and home-care providers are already moving beyond pilot mode and placing pre-orders - a strong signal that the product consistently delivers value in live environments.

A Market Ripe for Scalable Care Infrastructure

India’s aging population and overburdened care systems highlight an urgent need for automation. Pressure injury prevention alone represents an $8B+ addressable opportunity domestically, and the global market sits near $277B. As staffing shortages continue worldwide, solutions like Eturnal™ that combine patient safety with labor efficiency are becoming critical to healthcare’s operational infrastructure.

Why Investors Backed Cureous Labs

Both IPV and Anthill Ventures underscored the same point in their investment rationale: Cureous delivers measurable clinical improvement and operational leverage. In practice, that means fewer patient complications, reduced length of stay, and regained caregiver hours - all of which translate to better margins for hospitals and higher quality of care for patients.

Looking Ahead

Over the next year, Cureous Labs plans to:

• Deploy Eturnal™ in additional hospitals and rehab centers
  
• Tighten integrations with digital nursing and monitoring platforms
  
• Launch pilots in Australia and Southeast Asia, building on early clinical collaborations
  
• Begin R&D for expanded use cases focused on additional manual care routines
  

Cureous isn’t simply automating a single intervention - it’s building the blueprint for how repetitive, labor-heavy tasks in healthcare can be handled by smart, plug-and-play systems. And in a sector where small improvements in capacity translate into large-scale impact, that approach is not just convenient - it’s essential.